SOUTH SAN FRANCISCO, CA, USA I November 12, 2021 IKenjockety Biotechnology, Inc., an early-stage biotechnology company focused on discovery and development of novel therapeutics for the treatment of patients with drug-resistant cancers, today announced new data for their lead BsAb program targeting Pgp and CD47. These data will be shared in a poster presentation at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting in Washington, DC.
“These results demonstrate proof-of-concept for our lead bispecific antibody which is now ready for IND enabling studies,” said Robert Arathoon, PhD, Founder and CEO of Kenjockety Biotechnology. “With this novel approach we engineer bispecific antibodies to precisely target tumor but not normal cells, enabling enhanced efficacy while reducing toxicities seen with small molecules or monoclonal antibodies.”
The presentation includes preclinical results demonstrating in vivo efficacy for a Pgp X CD47 BsAb, both as monotherapy and in combination with paclitaxel in multiple tumor models. Kenjockety’s unique approach enables a multi-modal mechanism of action. This is achieved by antagonizing functional aspects of both targets: inhibiting Pgp to reduce drug resistance while targeting CD47 to enhance immune attack. Additionally, Kenjockety’s results illustrate tumor-specific targeting by engineering BsAbs to have strong binding only in the presence of both targets.
”Our proprietary BASE™ Platform facilitates the design and engineering of new therapeutics that antagonize Efflux Pumps, like Pgp, together with immuno-oncology targets, such as CD47 or other TAAs,” said Dr. Arathoon. “These therapeutics have the potential to provide significant clinical benefits for patients with a wide array of cancers.”
Presentation Information
Title: Bispecific Antibodies (BsAbs) Targeting ABCB1/P-Glycoprotein (Pgp) and CD47 Provide a Multimodal, Tumor-Specific Approach to Combat Drug-Resistant Cancers
Abstract Number: 282
Date/Time: Saturday, November 13th, 7:00 a.m. – 8:30 p.m.
Session: Poster and Exhibit Hall
Presenter: Dr. Robert Arathoon, Founder and CEO, Kenjockety Biotechnology, Inc.
About Kenjockety Biotechnology
Kenjockety Biotechnology is developing a new family of bispecific antibodies (BsAbs), addressing the significant unmet need of drug resistance for patients with cancer. Our proprietary BASE™ Platform supports an extensive pipeline of novel therapeutics by pairing our foundational antibodies antagonizing Efflux Pumps (EPs) with other Tumor Associated Antigen (TAA) targets, to construct BsAbs that more precisely target tumor versus normal cells. For more information, please visit www.kenjocketybio.com.
SOURCE: Kenjockety Biotechnology
Post Views: 68
SOUTH SAN FRANCISCO, CA, USA I November 12, 2021 IKenjockety Biotechnology, Inc., an early-stage biotechnology company focused on discovery and development of novel therapeutics for the treatment of patients with drug-resistant cancers, today announced new data for their lead BsAb program targeting Pgp and CD47. These data will be shared in a poster presentation at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting in Washington, DC.
“These results demonstrate proof-of-concept for our lead bispecific antibody which is now ready for IND enabling studies,” said Robert Arathoon, PhD, Founder and CEO of Kenjockety Biotechnology. “With this novel approach we engineer bispecific antibodies to precisely target tumor but not normal cells, enabling enhanced efficacy while reducing toxicities seen with small molecules or monoclonal antibodies.”
The presentation includes preclinical results demonstrating in vivo efficacy for a Pgp X CD47 BsAb, both as monotherapy and in combination with paclitaxel in multiple tumor models. Kenjockety’s unique approach enables a multi-modal mechanism of action. This is achieved by antagonizing functional aspects of both targets: inhibiting Pgp to reduce drug resistance while targeting CD47 to enhance immune attack. Additionally, Kenjockety’s results illustrate tumor-specific targeting by engineering BsAbs to have strong binding only in the presence of both targets.
”Our proprietary BASE™ Platform facilitates the design and engineering of new therapeutics that antagonize Efflux Pumps, like Pgp, together with immuno-oncology targets, such as CD47 or other TAAs,” said Dr. Arathoon. “These therapeutics have the potential to provide significant clinical benefits for patients with a wide array of cancers.”
Presentation Information
Title: Bispecific Antibodies (BsAbs) Targeting ABCB1/P-Glycoprotein (Pgp) and CD47 Provide a Multimodal, Tumor-Specific Approach to Combat Drug-Resistant Cancers
Abstract Number: 282
Date/Time: Saturday, November 13th, 7:00 a.m. – 8:30 p.m.
Session: Poster and Exhibit Hall
Presenter: Dr. Robert Arathoon, Founder and CEO, Kenjockety Biotechnology, Inc.
About Kenjockety Biotechnology
Kenjockety Biotechnology is developing a new family of bispecific antibodies (BsAbs), addressing the significant unmet need of drug resistance for patients with cancer. Our proprietary BASE™ Platform supports an extensive pipeline of novel therapeutics by pairing our foundational antibodies antagonizing Efflux Pumps (EPs) with other Tumor Associated Antigen (TAA) targets, to construct BsAbs that more precisely target tumor versus normal cells. For more information, please visit www.kenjocketybio.com.
SOURCE: Kenjockety Biotechnology
Post Views: 68
